APITOPE GROWS OPERATIONS WITH MOVE TO ST BRANDON’S HOUSE, BRISTOL, UK
Bristol, England / Hasselt, Belgium – 01 October 2010: Apitope International N.V., the biopharmaceutical company developing peptide therapies for autoimmune diseases, announced today that it has relocated its UK subsidiary HQ to larger premises at St Brandon’s House, 29 Great George Street, Bristol, BS1 5QT, UK, as a result of significant growth in Apitope’s business and staff. St Brandon’s House is a distinguished Grade II listed Georgian building ideally located in the heart of Bristol's business district but remaining close to the university.
Apitope was spun out of Bristol University in 2002, and since then has raised significant investment from specialist life sciences investors. In January 2009, Apitope signed an agreement with Merck Serono for the development and commercialisation of its lead product ATX-MS-1467. ATX-MS-1467 is a potentially disease-modifying therapy for the treatment of MS.

Keith Martin, CEO of Apitope said:
“Apitope has enjoyed a number of successful years in the Set Squared Centre at University Gate East and the larger premises at St Brandon’s House allow us to embark on the next phase of growth as we expand our management team, staff and business activities.”

- ends -